Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/a1/8e/44/a18e4428-3654-0b3c-8354-1413fac53568/mza_1159353289272426512.jpg/600x600bb.jpg
Air Street Press
Nathan Benaich (Air Street Capital)
97 episodes
1 week ago
As an AI-native investor, we believe it’s important to be a hands-on contributor to the community. Since our earliest days, we’ve been building in public - whether that’s sharing our perspectives on the direction of the field, emerging best practice for building AI-first companies, organizing meet-ups, and campaigning for policy change. Air Street Press brings together all of our content under one umbrella. Subscribe to listen to our analysis, portfolio news, Guide to AI monthly newsletter, annual State of AI Report, and our policy work.
Show more...
Technology
RSS
All content for Air Street Press is the property of Nathan Benaich (Air Street Capital) and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
As an AI-native investor, we believe it’s important to be a hands-on contributor to the community. Since our earliest days, we’ve been building in public - whether that’s sharing our perspectives on the direction of the field, emerging best practice for building AI-first companies, organizing meet-ups, and campaigning for policy change. Air Street Press brings together all of our content under one umbrella. Subscribe to listen to our analysis, portfolio news, Guide to AI monthly newsletter, annual State of AI Report, and our policy work.
Show more...
Technology
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/13558162/13558162-1717331901517-2b99014ba68f4.jpg
From move 37 to drug design
Air Street Press
5 minutes 35 seconds
3 months ago
From move 37 to drug design

At this year’s RAAIS, Max Jaderberg of Isomorphic Labs delivered a talk that felt like the spiritual sequel to AlphaGo, only this time the board isn’t 19×19, it’s the human body. The stakes? The future of drug discovery and human health.

Isomorphic Labs, the biotech spinout from DeepMind, has declared a radical mission: solving disease. It's not a metaphor. It’s a systems-level wager that the same kinds of models that cracked Go can crack biology. Not only by digitizing wet labs, but by encoding the dynamics of biomolecules into machine-learnable substrates. If AlphaGo marked the start of AI systems inventing strategies never before seen in human play, Isomorphic wants AI to invent medicines we’d never stumble across in the lab.

This is a moonshot, a bet that biology is information science, and machine learning is our best bet at learning its language.

Air Street Press
As an AI-native investor, we believe it’s important to be a hands-on contributor to the community. Since our earliest days, we’ve been building in public - whether that’s sharing our perspectives on the direction of the field, emerging best practice for building AI-first companies, organizing meet-ups, and campaigning for policy change. Air Street Press brings together all of our content under one umbrella. Subscribe to listen to our analysis, portfolio news, Guide to AI monthly newsletter, annual State of AI Report, and our policy work.